0.0001
0.0000
(0.00%)
At close: April 9 at 4:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Evan Mike Levine | Co-Founder, CEO & Chairman | 321k | -- | 1966 |
| Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D. | Chief Scientific Officer & Chief Medical Officer | 292.5k | -- | 1966 |
| Mr. Ross Carmel | Chief Legal Officer & Director | 131.67k | -- | 1982 |
| Mr. Noah Isidore Davis | Secretary & Director | 239.5k | -- | 1983 |
| Mr. Andrew Jones | Inventor & Chairman of Scientific Advisory Board | -- | -- | -- |
PsyBio Therapeutics Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
PsyBio Therapeutics Corp., a biotechnology company, engages in the research, development, and commercialization of psychedelic-inspired regulated medicines for the treatment of mental health and other disorders in the United States. PsyBio Therapeutics Corp. was formerly known as Leo Acquisitions Corp. and changed its name to PsyBio Therapeutics Corp. in January 2021. The company is headquartered in Denver, Colorado.
Corporate Governance
PsyBio Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
Upcoming Events Information Not Available
Recent Events
October 18, 2016 at 12:00 AM UTC
Dividend Date